ClinicalTrials.gg
RecruitingNCT06773845BEAT-UT7Updated Aug 20, 2026

Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria

A Phase 2 interventional study of TheraSphere in Hepatocellular Carcinoma (HCC) and Radioembolization, sponsored by Seoul National University Hospital. Recruiting at 8 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Seoul National University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital — 9 open to participants now, 14 under way, none of them phase 3. Carcinoma, Hepatocellular · Seoul National University Hospital.

Planned enrollment
21st of 52
100 · median 85
Started
2025
with 2 others
Phase 2
12 of 61
3 open now
Primary completion
2028-12
later than 10 of 13 live
Registered
56th of 61
by date

Among the 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital, this one is the 21st largest by planned enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 10 of the 13 other live ones, and was the 56th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital, or all of them as a file.
02

Study summary

At four major centers in Korea, patients with hepatocellular carcinoma (HCC) that exceed the up-to-7 criteria yet remain locally confined will undergo ablative radioembolization using Yttrium-90 glass microspheres, guided by a standardized dosimetry method. Their treatment response, survival outcomes, and adverse events will be monitored for two years following the procedure.

Read the detailed description

This prospective, multi-center, open-label, single-arm, phase II clinical trial aims to evaluate the efficacy and safety of ablative radioembolization in patients with hepatocellular carcinoma (HCC) that exceeds the up-to-seven (UT7) criteria but is confined to up to five geographically adjacent Couinaud segments. The primary endpoint is the objective response rate, assessed according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST).

All patients will receive ablative radioembolization using Yttrium-90 glass microspheres with a personalized dosimetry approach targeting a tumor dose of 700 Gy (±50%). In cases of high tumor burden, a second radioembolization within 180 days of the initial procedure will be permitted at the operators' discretion, provided the cumulative lung dose remains below 50 Gy. Follow-up evaluations, including laboratory tests and dynamic imaging, will be performed at 4 weeks post-treatment and every 3 months thereafter for a total of 2 years. Efficacy data-including tumor response and survival-will be collected, with tumor responses evaluated by both site investigators and a blinded independent central review. Adverse events will be documented and graded according to the Common Terminology Criteria for Adverse Events v5.0. In addition, the incidence of radioembolization-induced liver disease and radiation pneumonitis will be monitored for 6 months following the procedure.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
  • Radioembolization

Keywords

  • Hepatocellular carcinoma
  • Radioembolization
  • SIRT
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult aged 19 and over
  • HCC diagnosed by histology or non-invasive criteria of the American Association for the Study of Liver Disease
  • Unresectable HCC beyond the UT7 criteria: the sum of the diameter of the largest tumor (cm) and the number of tumors > 7
  • Localized HCC: all tumors are in the one to five geographically adjacent Couinaud segments
  • No current or previous HCC in the untreated liver (i.e., future liver remnant [FLR])
  • FLR volume > 30% of total non-tumorous liver volume
  • class A
  • (ECOG) performance status ≤ 1
  • No major organ dysfunction according to blood test performed within two months of study enrollment:

    • Leukocytes ≥ 2,000/µL and ≤ 15,000/µL
    • ≥ 8.0 g/dL (transfusion allowed to meet this criterion)
    • Total ≤ 2.0 mg/dL
    • ≥ 40,000/µL
    • (INR) ≤ 2.0 for patients not taking anticoagulants
    • (AST) ≤ 200 IU/L (i.e., ≤ 5X upper normal limit)
    • Alanine transaminase (ALT) ≤ 200 IU/L (i.e., ≤ 5X upper normal limit)
    • Creatinine ≤ 2.5 mg/dL
  • Patients with a of more than 3 months
  • For women of childbearing age, a negative serum pregnancy test
  • Patients who have adequately understood the clinical trial and consented in writing

Exclusion criteria

Exclusion Criteria:

  • HCC with vascular invasion and/or bile duct invasion on dynamic computed tomography (CT) or magnetic resonance imaging (MRI)
  • HCC with extrahepatic spread on chest CT and abdominal CT or MRI
  • Multinodular disseminated HCC: largest tumor size \< 6 cm, or number of tumors > 10
  • Patients who are not suitable for ablative radioembolization as indicated by pre-treatment mapping with 99mTc-macroaggregated albumin (MAA):

    • Cases where the estimated lung dose exceeds 30 Gy when 350 Gy of tumor absorbed dose is administered to the tumor based on the multicompartment Medical Internal Radiation Dose (MIRD) model
    • Cases with severe hepatic artery-portal vein shunting that might lead to irradiation of the non-tumorous liver segments
    • Cases where the operator determines that there is substantial adhesion with the surrounding organs such as the bowel, making ablative radioembolization infeasible
  • Cases where the operator judges that the occurrence of even mild radiation pneumonitis could be fatal, based on marked emphysema or interstitial lung disease findings on chest CT
  • Patients who have had active cancer within the last two years prior to the study enrollment
  • History of severe allergy of intolerance to contrast agents
  • to angiography or selective visceral catheterization
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Radioembolization

    Ablative radioembolization using Yttrium-90 glass microspheres

    Device: TheraSphere

Interventions

  • DeviceTheraSphere

    The multicompartment MIRD model (a.k.a. partition model) based on diagnostic CT/MRI and 99mTc-MAA SPECT-CT will be used to plan a targeted dose of 700 Gy (± 50%) to the tumor. Given the high tumor burden, a scheduled second radioembolization within 120 days from the initial treatment will be permitted at the discretion of the operators provided the cumulative lung dose remains below 50 Gy. A scheduled second radioembolization may be considered when the largest tumor diameter exceeds 8 cm, or the estimated lung dose reaches 30 Gy while the tumor absorbed dose remains below the target dose of 700 Gy. The radioactive microsphere delivery device used will be glass-based (TheraSphere; Boston Scientific, MA, USA), in which Y90 is an integral constituent of the biocompatible glass matrix. Dosimetry planning will be made by personalized dosimetry software (Simplicit90y; Boston Scientific).

    Also known as: Y90 glass microsphere

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) according to the mRECIST

    The number of patients with partial or complete response accroding to the mRECIST as the best response, divided by the total number of participants (%)

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

Secondary outcomes

  1. ORR according to the RECIST 1.1

    The number of patients with partial or complete response according to the RECIST 1.1 as the best response, divided by the total number of participants (%)

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  2. ORR according to localized mRECIST and RECIST 1.1

    The number of patients with partial or complete response as the best response, divided by the total number of participants (%). In the localized mRECIST and RECIST 1.1, the tumor response is assessed only within radioembolization-treated area.

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  3. Duration of response according to mRECIST, localized mRECIST, and RECIST 1.1

    The time from the first documentation of partial or complete response to the first occurrence of progressive disease, death from any cause, or receipt of subsequent anticancer treatment, whichever comes first.

    Time frame: Time of response up to progression, subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  4. Overall survival rate

    Time frame: Time of treatment up to participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  5. Progression-free survival rates according to mRECIST, localized mRECIST, and RECIST 1.1

    Time frame: Time of treatment up to progression, subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  6. Time-to-progression according to mRECIST, localized mRECIST, and RECIST 1.1

    Time frame: Time of treatment up to progression, subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled).

  7. Major pathologic response rate (%) after surgical resection or liver transplantation

    The number of patients with major pathologic response of the largest tumor after surgical resection or liver transplantation, divided by the total number of participants who received surgical resection or liver transplanation (%). Major pathologic response refers to ≥ 90% of pathologic necrosis of the largest resected tumor

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  8. Curative conversion rate

    Curative conversion: resection, liver transplantation, or percutaneous ablation

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  9. Sustainable complete response rate according to mRECIST more than 1 year

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  10. Locoregional treatment unsuitability rate

    LRT unsuitability will be determined if any of the following criteria are met. * Lack of objective response after two sessions of intra-arterial treatments * Development of new HCC within the treatment zone * Development of vascular invasion within the treatment zone * Development of extrahepatic spread

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  11. Time to and reason for subsequent HCC treatment

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  12. Threshold tumor absorbed dose (Gy) to predict radiologic complete response and objective response as the best response by localized mRECIST

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  13. Adverse event and serious adverse event according to CTCAE v5.0

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  14. The presence or absence of radiation pneumonitis diagnosed by chest simple X-ray or CT

    Time frame: Time of treatment up to 180 days after the initial treatment or subsequent anticancer treatment, whichever comes first

  15. The presence or absence of radioembolization-induced liver disease

    Time frame: Time of treatment up to 180 days after the initial treatment or subsequent anticancer treatment, whichever comes first

07

Study locations

7 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2028, 45 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 45 months is close to that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 14, 2025
StartActual
Mar 11, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06773845
Responsible party
Jin Woo Choi (Clinical Associate Professor, Seoul National University Hospital) — Principal investigator
First posted
Jan 14, 2025
Start date
Mar 11, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 20, 2026

Study contacts

Hyun Hee Lee
Contact
redlion55@snu.ac.kr
+82 220724177
Mina Lee
Contact
mina.lee@bsci.com
Jin Woo Choi, MD, PhD
study chair · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion